Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News CytomX Therapeutics Inc CTMX

Healthcare Biotechnology
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CTMX)

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 13 days ago

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

GlobeNewswire October 31, 2024

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

GlobeNewswire September 9, 2024

CytomX Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewswire September 4, 2024

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire August 8, 2024

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire August 1, 2024

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

GlobeNewswire June 18, 2024

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

GlobeNewswire June 17, 2024

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 22, 2024
View More News ››

Opinion & Analysis (NDAQ:CTMX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CTMX)

Analysts' Varied Perspectives On CytomX's CX-904 Cancer Stud

Just In: $CTMX Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer...
whytestocks - May 9, 2024

The report

So. Nothing tilt he end of the year, then nothign til t eend of next year.  Hmmph.
zalmonella - May 9, 2024

CTMX Price Target Alert: $8.00. Issued by Jefferies

Just In: $CTMX CTMX Price Target Alert: $8.00. Issued by Jefferies2024-05-06 00:00:04 ET Roger Song from Jefferies issued a price target...
whytestocks - May 6, 2024

CTMX..... Early a.m runner

On watch  Going Skiing...no position  Cheers !
Iseneschal - January 6, 2023

From boom to boot

Nice rise throughoutthe week, adn then last trad of the day on the 1st for 780,00 shars at whatever the market would get for it...
zalmonella - February 2, 2022

EMERGING PARADIGMS IN TREATMENT OF MELANOMA!

$CTMX $NKTR $MGNX $IDYA $ALKS Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7...
AviseAnalytics - January 26, 2022
View more Bullboard ››

Regenx Tech Corp.

Regenx Tech Corp.

Regenx Tech Corp. is a cleantech company. The Company is engaged in the development and commercialization of its processing ...
View More »